Skip to main content

Advertisement

SpringerLink
Log in

Liquid Biopsy and its Potential for Management of Hepatocellular Carcinoma

  • Review Article
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Purpose

We summarized the recent findings of liquid biopsy in cancer field and discussed its potential utility in hepatocellular carcinoma.

Methods

Literature published in MEDLINE, EMBASE, and Science Direct electronic databases was searched and reviewed.

Results

Liquid biopsy specially referred to the detection of nucleic acids (circulating cell-free DNA, cfDNA) and circulating tumor cells (CTCs) in the blood of cancer patients. Compared to conventional single-site sampling or biopsy method, liquid biopsy had the advantages such as non-invasiveness, dynamic monitoring, and the most important of all, overcoming the limit of spatial and temporal heterogeneity. The genomic information of cancer could be profiled by genotyping cfDNA/CTC and subsequently applied to make molecular classification, targeted therapy guidance, and unveil drug resistance mechanisms. The serial sampling feature of liquid biopsy made it possible to monitor treatment response in a real-time manner and predict tumor metastasis/recurrence in advance.

Conclusions

Liquid biopsy is a non-invasive, dynamic, and informative sampling method with important clinical translational significance in cancer research and practice. Much work needs to be done before it is used in the management of HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kruglyak KM, Lin E, Ong FS. Next-generation sequencing in precision oncology: challenges and opportunities. Expert Rev Mol Diagn. 2014;14(6):635–7.

    Article  CAS  PubMed  Google Scholar 

  2. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10(8):472–84.

    Article  CAS  PubMed  Google Scholar 

  3. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–92.

    Article  CAS  PubMed  Google Scholar 

  4. Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet. 2014;46(3):225–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395–9.

    CAS  PubMed  Google Scholar 

  6. de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science (New York, NY). 2014;346(6206):251–6.

    Article  CAS  Google Scholar 

  7. Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science (New York, NY). 2014;346(6206):256–9.

    Article  CAS  Google Scholar 

  8. Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y, et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet. 2015;47(5):458–68.

    Article  CAS  PubMed  Google Scholar 

  9. Schwarz RF, Ng CK, Cooke SL, Newman S, Temple J, Piskorz AM, et al. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. PLoS Med. 2015;12(2):e1001789.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Friemel J, Rechsteiner M, Frick L, Bohm F, Struckmann K, Egger M, et al. Intratumor heterogeneity in hepatocellular carcinoma. Clin Cancer Res: Off J Am Assoc Cancer Res. 2015;21(8):1951–61.

    Article  CAS  Google Scholar 

  11. Gawad C, Koh W, Quake SR. Dissecting the clonal origins of childhood acute lymphoblastic leukemia by single-cell genomics. Proc Natl Acad Sci U S A. 2014;111(50):17947–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Landau DA, Clement K, Ziller MJ, Boyle P, Fan J, Gu H, et al. Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell. 2014;26(6):813–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Oakes CC, Claus R, Gu L, Assenov Y, Hullein J, Zucknick M, et al. Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. Cancer Discov. 2014;4(3):348–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Jamal-Hanjani M, Quezada SA, Larkin J, Swanton C. Translational implications of tumor heterogeneity. Clin Cancer Res: Off J Am Assoc Cancer Res. 2015;21(6):1258–66.

    Article  CAS  Google Scholar 

  15. McGranahan N, Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell. 2015;27(1):15–26.

    Article  CAS  PubMed  Google Scholar 

  16. McCreery MQ, Halliwill KD, Chin D, Delrosario R, Hirst G, Vuong P, et al. Evolution of metastasis revealed by mutational landscapes of chemically induced skin cancers. Nature Med. 2015;21(12):1514–20.

  17. Alix-Panabieres C, Pantel K. Real-time liquid biopsy: circulating tumor cells versus circulating tumor DNA. Ann Transl Med. 2013;1(2):18.

    PubMed  PubMed Central  Google Scholar 

  18. Lebofsky R, Decraene C, Bernard V, Kamal M, Blin A, Leroy Q, et al. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol Oncol. 2015;9(4):783–90.

    Article  CAS  PubMed  Google Scholar 

  19. Lianos GD, Mangano A, Kouraklis G, Roukos DH. Dynamic sequencing of circulating tumor DNA: novel noninvasive cancer biomarker. Biomark Med. 2014;8(5):629–32.

    Article  CAS  PubMed  Google Scholar 

  20. Rothe F, Laes JF, Lambrechts D, Smeets D, Vincent D, Maetens M, et al. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol: Off J Eur Soc Med Oncol / ESMO. 2014;25(10):1959–65.

    Article  CAS  Google Scholar 

  21. Zhu G, Ye X, Dong Z, Lu Y, Sun Y, Liu Y, et al. Highly sensitive droplet digital PCR method for detection of EGFR activating mutations in plasma cell-free DNA from patients with advanced Non-small cell lung cancer. J Mol Diagn: JMD. 2015;17(3):265–72.

    Article  CAS  PubMed  Google Scholar 

  22. Pantel K, Speicher MR. The biology of circulating tumor cells. Oncogene. 2015. doi:10.1038/onc.2015.192.

  23. Yap TA, Lorente D, Omlin A, Olmos D, de Bono JS. Circulating tumor cells: a multifunctional biomarker. Clin Cancer Res: Off J Am Assoc Cancer Res. 2014;20(10):2553–68.

    Article  CAS  Google Scholar 

  24. Caceres G, Puskas JA, Magliocco AM. Circulating tumor cells: a window into tumor development and therapeutic effectiveness. Cancer Control: J Moffitt Cancer Cent. 2015;22(2):167–76.

    Google Scholar 

  25. Schneck H, Blassl C, Meier-Stiegen F, Neves RP, Janni W, Fehm T, et al. Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients. Mol Oncol. 2013;7(5):976–86.

    Article  CAS  PubMed  Google Scholar 

  26. Polzer B, Medoro G, Pasch S, Fontana F, Zorzino L, Pestka A, et al. Molecular profiling of single circulating tumor cells with diagnostic intention. EMBO Mol Med. 2014;6(11):1371–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Hao TB, Shi W, Shen XJ, Qi J, Wu XH, Wu Y, et al. Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer. Br J Cancer. 2014;111(8):1482–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Shin VY, Siu JM, Cheuk I, Ng EK, Kwong A. Circulating cell-free miRNAs as biomarker for triple-negative breast cancer. Br J Cancer. 2015;112(11):1751–9.

    Article  CAS  PubMed  Google Scholar 

  29. Singh N, Gupta S, Pandey RM, Chauhan SS, Saraya A. High levels of cell-free circulating nucleic acids in pancreatic cancer are associated with vascular encasement, metastasis and poor survival. Cancer Investig. 2015;33(3):78–85.

    Article  CAS  Google Scholar 

  30. Zonta E, Nizard P, Taly V. Assessment of DNA integrity, applications for cancer research. Adv Clin Chem. 2015;70:197–246.

    Article  PubMed  Google Scholar 

  31. Sausen M, Parpart S, Diaz Jr LA. Circulating tumor DNA moves further into the spotlight. Genome Med. 2014;6(5):35.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. Bidard FC, Weigelt B, Reis-Filho JS. Going with the flow: from circulating tumor cells to DNA. Sci Transl Med. 2013;5(207):207ps14.

    Article  PubMed  CAS  Google Scholar 

  33. Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 2015;61(1):112–23.

    Article  CAS  PubMed  Google Scholar 

  34. Matamala N, Vargas MT, Gonzalez-Campora R, Minambres R, Arias JI, Menendez P, et al. Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection. Clin Chem. 2015;61(8):1098–106.

    Article  CAS  PubMed  Google Scholar 

  35. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 2010;28(10):1721–6.

    Article  Google Scholar 

  36. Verma AM, Patel M, Aslam MI, Jameson J, Pringle JH, Wurm P, et al. Circulating plasma microRNAs as a screening method for detection of colorectal adenomas. Lancet. 2015;385 Suppl 1:S100.

    Article  PubMed  Google Scholar 

  37. Hu J, Wang Z, Liao BY, Yu L, Gao X, Lu S, et al. Human miR-1228 as a stable endogenous control for the quantification of circulating microRNAs in cancer patients. Int J Cancer. 2014;135(5):1187–94.

    Article  CAS  PubMed  Google Scholar 

  38. Aushev VN, Zborovskaya IB, Laktionov KK, Girard N, Cros MP, Herceg Z, et al. Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma. PLoS One. 2013;8(10):e78649.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Nair VS, Maeda LS, Ioannidis JP. Clinical outcome prediction by microRNAs in human cancer: a systematic review. J Natl Cancer Inst. 2012;104(7):528–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Thery C. Cancer: diagnosis by extracellular vesicles. Nature. 2015;523(7559):161–2.

    Article  CAS  PubMed  Google Scholar 

  41. Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD, Kloecker GH. Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer. 2009;10(1):42–6.

    Article  CAS  PubMed  Google Scholar 

  42. Hornick NI, Huan J, Doron B, Goloviznina NA, Lapidus J, Chang BH, et al. Serum exosome microRNA as a minimally-invasive early biomarker of AML. Sci Rep. 2015;5:11295.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Matsumura T, Sugimachi K, Iinuma H, Takahashi Y, Kurashige J, Sawada G, et al. Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. Br J Cancer. 2015;113(2):275–81.

    Article  CAS  PubMed  Google Scholar 

  44. Shi R, Wang PY, Li XY, Chen JX, Li Y, Zhang XZ, et al. Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients. Oncotarget. 2015;6(29):26971–81.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Lee JC, Zhao JT, Gundara J, Serpell J, Bach LA, Sidhu S. Papillary thyroid cancer-derived exosomes contain miRNA-146b and miRNA-222. J Surg Res. 2015;196(1):39–48.

    Article  CAS  PubMed  Google Scholar 

  46. Chiam K, Wang T, Watson DI, Mayne GC, Irvine TS, Bright T, et al. Circulating serum exosomal miRNAs as potential biomarkers for esophageal adenocarcinoma. J Gastrointest Surg: Off J Soc Surg Aliment Tract. 2015;19(7):1208–15.

    Article  Google Scholar 

  47. Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523(7559):177–82.

    Article  CAS  PubMed  Google Scholar 

  48. Overbye A, Skotland T, Koehler CJ, Thiede B, Seierstad T, Berge V, et al. Identification of prostate cancer biomarkers in urinary exosomes. Oncotarget. 2015;6(30):30357–76.

    PubMed  PubMed Central  Google Scholar 

  49. Tokuhisa M, Ichikawa Y, Kosaka N, Ochiya T, Yashiro M, Hirakawa K, et al. Exosomal miRNAs from peritoneum lavage fluid as potential prognostic biomarkers of peritoneal metastasis in gastric cancer. PLoS One. 2015;10(7):e0130472.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  50. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res: Off J Am Assoc Cancer Res. 2004;10(20):6897–904.

    Article  Google Scholar 

  51. Coumans F, Terstappen L. Detection and characterization of circulating tumor cells by the CellSearch approach. Methods Mol Biol (Clifton, NJ). 2015;1347:263–78.

    Article  Google Scholar 

  52. Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C. Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol. 2014;11(3):129–44.

    Article  CAS  PubMed  Google Scholar 

  53. Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med. 2013;5(179):179ra47.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  54. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450(7173):1235–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Hou HW, Warkiani ME, Khoo BL, Li ZR, Soo RA, Tan DS, et al. Isolation and retrieval of circulating tumor cells using centrifugal forces. Sci Rep. 2013;3:1259.

    PubMed  PubMed Central  Google Scholar 

  56. He W, Wang H, Hartmann LC, Cheng JX, Low PS. In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry. Proc Natl Acad Sci U S A. 2007;104(28):11760–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Somlo G, Lau SK, Frankel P, Hsieh HB, Liu X, Yang L, et al. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res Treat. 2011;128(1):155–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Sarioglu AF, Aceto N, Kojic N, Donaldson MC, Zeinali M, Hamza B, et al. A microfluidic device for label-free, physical capture of circulating tumor cell clusters. Nat Methods. 2015;12(7):685–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Fabbri F, Carloni S, Zoli W, Ulivi P, Gallerani G, Fici P, et al. Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs. Cancer Lett. 2013;335(1):225–31.

    Article  CAS  PubMed  Google Scholar 

  60. He Y, Lin J, Kong D, Huang M, Xu C, Kim TK, et al. Current state of circulating microRNAs as cancer biomarkers. Clin Chem. 2015;61(9):1138–55.

    Article  CAS  PubMed  Google Scholar 

  61. McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A. Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem. 2011;57(6):833–40.

    Article  CAS  PubMed  Google Scholar 

  62. El Messaoudi S, Rolet F, Mouliere F, Thierry AR. Circulating cell free DNA: preanalytical considerations. Clin Chim Acta; Int J Clin Chem. 2013;424:222–30.

    Article  CAS  Google Scholar 

  63. Martinez P, McGranahan N, Birkbak NJ, Gerlinger M, Swanton C. Computational optimisation of targeted DNA sequencing for cancer detection. Sci Rep. 2013;3:3309.

    Article  PubMed  Google Scholar 

  64. Leary RJ, Kinde I, Diehl F, Schmidt K, Clouser C, Duncan C, et al. Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med. 2010;2(20):20ra14.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  65. Mohamed Suhaimi NA, Foong YM, Lee DY, Phyo WM, Cima I, Lee EX, et al. Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients. Mol Oncol. 2015;9(4):850–60.

    Article  CAS  PubMed  Google Scholar 

  66. Marchetti A, Del Grammastro M, Felicioni L, Malatesta S, Filice G, Centi I, et al. Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment. PLoS One. 2014;9(8):e103883.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  67. Pestrin M, Salvianti F, Galardi F, De Luca F, Turner N, Malorni L, et al. Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. Mol Oncol. 2015;9(4):749–57.

    Article  CAS  PubMed  Google Scholar 

  68. Sykes PJ, Neoh SH, Brisco MJ, Hughes E, Condon J, Morley AA. Quantitation of targets for PCR by use of limiting dilution. Biotechniques. 1992;13(3):444–9.

    CAS  PubMed  Google Scholar 

  69. Hudecova I. Digital PCR, analysis of circulating nucleic acids. Clin Biochem. 2015;48(15):948–56.

    Article  CAS  PubMed  Google Scholar 

  70. Zhang BO, Xu CW, Shao Y, Wang HT, Wu YF, Song YY, et al. Comparison of droplet digital PCR and conventional quantitative PCR for measuring gene mutation. Exp Ther Med. 2015;9(4):1383–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  71. Huggett JF, Cowen S, Foy CA. Considerations for digital PCR as an accurate molecular diagnostic tool. Clin Chem. 2015;61(1):79–88.

    Article  CAS  PubMed  Google Scholar 

  72. Stewart GD, O’Mahony F, Laird A, Eory L, Lubbock A, Mackay A, et al. Sunitinib treatment exacerbates intratumoral heterogeneity in metastatic renal cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2015;21(18):4212–23.

    Article  CAS  Google Scholar 

  73. Tsao SC, Weiss J, Hudson C, Christophi C, Cebon J, Behren A, et al. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. Sci Rep. 2015;5:11198.

    Article  PubMed  CAS  Google Scholar 

  74. Zill OA, Greene C, Sebisanovic D, Siew L, Leng J, Vu M, et al. Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas. Cancer Discov. 2015;5(10):1040–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21(7):795–801.

    Article  CAS  PubMed  Google Scholar 

  76. Watanabe M, Kawaguchi T, Isa SI, Ando M, Tamiya A, Kubo A, et al. Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small-cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR. Clin Cancer Res: Off J Am Assoc Cancer Res. 2015;21(15):3552–60.

    Article  CAS  Google Scholar 

  77. Mishra PJ. MicroRNAs as promising biomarkers in cancer diagnostics. Biomarker Res. 2014;2:19.

    Article  Google Scholar 

  78. Patel M, Verma A, Aslam I, Pringle H, Singh B. Novel plasma microRNA biomarkers for the identification of colitis-associated carcinoma. Lancet. 2015;385 Suppl 1:S78.

    Article  PubMed  Google Scholar 

  79. Fang Z, Tang J, Bai Y, Lin H, You H, Jin H, et al. Plasma levels of microRNA-24, microRNA-320a, and microRNA-423-5p are potential biomarkers for colorectal carcinoma. J Exp Clin Cancer Res: CR. 2015;34(1):86.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  80. Zhou X, Zhu W, Li H, Wen W, Cheng W, Wang F, et al. Diagnostic value of a plasma microRNA signature in gastric cancer: a microRNA expression analysis. Sci Rep. 2015;5:11251.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Schultz NA, Dehlendorff C, Jensen BV, Bjerregaard JK, Nielsen KR, Bojesen SE, et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA. 2014;311(4):392–404.

    Article  CAS  PubMed  Google Scholar 

  82. Li N, Ma J, Guarnera MA, Fang H, Cai L, Jiang F. Digital PCR quantification of miRNAs in sputum for diagnosis of lung cancer. J Cancer Res Clin Oncol. 2014;140(1):145–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2011;29(36):4781–8.

    Article  CAS  Google Scholar 

  84. Hamakawa T, Kukita Y, Kurokawa Y, Miyazaki Y, Takahashi T, Yamasaki M, et al. Monitoring gastric cancer progression with circulating tumour DNA. Br J Cancer. 2015;112(2):352–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Roschewski M, Dunleavy K, Pittaluga S, Moorhead M, Pepin F, Kong K, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015;16(5):541–9.

    Article  PubMed  Google Scholar 

  86. Sausen M, Phallen J, Adleff V, Jones S, Leary RJ, Barrett MT, et al. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun. 2015;6:7686.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Tie J, Kinde I, Wang Y, Wong HL, Roebert J, Christie M, et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol: Off J Eur Soc Med Oncol / ESMO. 2015;26(8):1715–22.

    Article  CAS  Google Scholar 

  88. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–67.

    Article  CAS  PubMed  Google Scholar 

  89. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46.

    Article  CAS  PubMed  Google Scholar 

  90. Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 2009;27(16):2653–9.

    Article  CAS  Google Scholar 

  91. Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21(6):560–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008;359(4):366–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Morelli MP, Overman MJ, Dasari A, Kazmi SM, Mazard T, Vilar E, et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol: Off J Eur Soc Med Oncol / ESMO. 2015;26(4):731–6.

    Article  CAS  Google Scholar 

  94. Diaz Jr LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486(7404):537–40.

    CAS  PubMed  PubMed Central  Google Scholar 

  95. Mohan S, Heitzer E, Ulz P, Lafer I, Lax S, Auer M, et al. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet. 2014;10(3):e1004271.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  96. Hiltermann TJ, Pore MM, van den Berg A, Timens W, Boezen HM, Liesker JJ, et al. Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann Oncol: Off J Eur Soc Med Oncol / ESMO. 2012;23(11):2937–42.

    Article  CAS  Google Scholar 

  97. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res: Off J Am Assoc Cancer Res. 2006;12(14 Pt 1):4218–24.

    Article  CAS  Google Scholar 

  98. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 2008;26(19):3213–21.

    Article  Google Scholar 

  99. Liu Y, Liu Q, Wang T, Bian L, Zhang S, Hu H, et al. Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker. BMC Cancer. 2013;13:202.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol: Off J Am Soc Clin Oncol. 2014;32(31):3483–9.

    Article  CAS  Google Scholar 

  101. Zhang Y, Li J, Cao L, Xu W, Yin Z. Circulating tumor cells in hepatocellular carcinoma: detection techniques, clinical implications, and future perspectives. Semin Oncol. 2012;39(4):449–60.

    Article  CAS  PubMed  Google Scholar 

  102. Sun YF, Xu Y, Yang XR, Guo W, Zhang X, Qiu SJ, et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology (Baltimore, Md). 2013;57(4):1458–68.

    Article  CAS  Google Scholar 

  103. Liu S, Li N, Yu X, Xiao X, Cheng K, Hu J, et al. Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells. Gastroenterology. 2013;144(5):1031–41.e10.

    Article  PubMed  CAS  Google Scholar 

  104. Yan J, Fan Z, Wu X, Xu M, Jiang J, Tan C, et al. Circulating tumor cells are correlated with disease progression and treatment response in an orthotopic hepatocellular carcinoma model. Cytometry A: J Int Soc Anal Cytol. 2015;87(11):1020–8.

    Article  CAS  Google Scholar 

  105. Guo W, Yang XR, Sun YF, Shen MN, Ma XL, Wu J, et al. Clinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR-based platform. Clin Cancer Res: Off J Am Assoc Cancer Res. 2014;20(18):4794–805.

    Article  CAS  Google Scholar 

  106. Kelley RK, Magbanua MJ, Butler TM, Collisson EA, Hwang J, Sidiropoulos N, et al. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. BMC Cancer. 2015;15:206.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Azvolinsky A. Beyond counting: new way to use circulating tumor cells. J Natl Cancer Inst. 2014;106(10):dju343.

  108. Zhou J, Shi YH, Fan J. Circulating cell-free nucleic acids: promising biomarkers of hepatocellular carcinoma. Semin Oncol. 2012;39(4):440–8.

    Article  CAS  PubMed  Google Scholar 

  109. Wong IH, Lo YM, Zhang J, Liew CT, Ng MH, Wong N, et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res. 1999;59(1):71–3.

    CAS  PubMed  Google Scholar 

  110. Wong IH, Lo YM, Yeo W, Lau WY, Johnson PJ. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin Cancer Res: Off J Am Assoc Cancer Res. 2000;6(9):3516–21.

    CAS  Google Scholar 

  111. Wong IH, Zhang J, Lai PB, Lau WY, Lo YM. Quantitative analysis of tumor-derived methylated p16INK4a sequences in plasma, serum, and blood cells of hepatocellular carcinoma patients. Clin Cancer Res: Off J Am Assoc Cancer Res. 2003;9(3):1047–52.

    CAS  Google Scholar 

  112. Chan KC, Lai PB, Mok TS, Chan HL, Ding C, Yeung SW, et al. Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. Clin Chem. 2008;54(9):1528–36.

    Article  CAS  PubMed  Google Scholar 

  113. Huang G, Krocker JD, Kirk JL, Merwat SN, Ju H, Soloway RD, et al. Evaluation of INK4A promoter methylation using pyrosequencing and circulating cell-free DNA from patients with hepatocellular carcinoma. Clin Chem Lab Med: CCLM / FESCC. 2014;52(6):899–909.

    Article  CAS  Google Scholar 

  114. Xu H, Zhu X, Xu Z, Hu Y, Bo S, Xing T, et al. Non-invasive analysis of genomic copy number variation in patients with hepatocellular carcinoma by next generation DNA sequencing. J Cancer. 2015;6(3):247–53.

    Article  PubMed  PubMed Central  Google Scholar 

  115. Huang XH, Sun LH, Lu DD, Sun Y, Ma LJ, Zhang XR, et al. Codon 249 mutation in exon 7 of p53 gene in plasma DNA: maybe a new early diagnostic marker of hepatocellular carcinoma in Qidong risk area, China. World J Gastroenterol: WJG. 2003;9(4):692–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Szymanska K, Lesi OA, Kirk GD, Sam O, Taniere P, Scoazec JY, et al. Ser-249TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in the Gambia, West Africa. Int J Cancer J Int Cancer. 2004;110(3):374–9.

    Article  CAS  Google Scholar 

  117. Kirk GD, Lesi OA, Mendy M, Szymanska K, Whittle H, Goedert JJ, et al. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene. 2005;24(38):5858–67.

    Article  CAS  PubMed  Google Scholar 

  118. Hu J, Wang Z, Fan J, Dai Z, He YF, Qiu SJ, et al. Genetic variations in plasma circulating DNA of HBV-related hepatocellular carcinoma patients predict recurrence after liver transplantation. PLoS One. 2011;6(10):e26003.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Ren N, Qin LX, Tu H, Liu YK, Zhang BH, Tang ZY. The prognostic value of circulating plasma DNA level and its allelic imbalance on chromosome 8p in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2006;132(6):399–407.

    Article  CAS  PubMed  Google Scholar 

  120. Ren N, Ye QH, Qin LX, Zhang BH, Liu YK, Tang ZY. Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients. World J Gastroenterol: WJG. 2006;12(24):3911–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Iizuka N, Sakaida I, Moribe T, Fujita N, Miura T, Stark M, et al. Elevated levels of circulating cell-free DNA in the blood of patients with hepatitis C virus-associated hepatocellular carcinoma. Anticancer Res. 2006;26(6c):4713–9.

    CAS  PubMed  Google Scholar 

  122. Iida M, Iizuka N, Sakaida I, Moribe T, Fujita N, Miura T, et al. Relation between serum levels of cell-free DNA and inflammation status in hepatitis C virus-related hepatocellular carcinoma. Oncol Rep. 2008;20(4):761–5.

    CAS  PubMed  Google Scholar 

  123. Tokuhisa Y, Iizuka N, Sakaida I, Moribe T, Fujita N, Miura T, et al. Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma. Br J Cancer. 2007;97(10):1399–403.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Giordano S, Columbano A. MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology (Baltimore, Md). 2013;57(2):840–7.

    Article  CAS  Google Scholar 

  125. Hung CH, Hu TH, Lu SN, Kuo FY, Chen CH, Wang JH, et al. Circulating microRNAs as biomarkers for diagnosis of early hepatocellular carcinoma associated with hepatitis B virus. Int J Cancer J Int Cancer. 2015. doi:10.1002/ijc.29802.

    Google Scholar 

  126. Motawi TK, Shaker OG, El-Maraghy SA, Senousy MA. Serum microRNAs as potential biomarkers for early diagnosis of hepatitis C virus-related hepatocellular carcinoma in Egyptian patients. PLoS One. 2015;10(9):e0137706.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  127. Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol. 2011;45(4):355–60.

    Article  CAS  PubMed  Google Scholar 

  128. Fu Y, Wei X, Tang C, Li J, Liu R, Shen A, et al. Circulating microRNA-101 as a potential biomarker for hepatitis B virus-related hepatocellular carcinoma. Oncol Lett. 2013;6(6):1811–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  129. Wang H, Hou L, Li A, Duan Y, Gao H, Song X. Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma. BioMed Res Int. 2014;2014:864894.

    PubMed  PubMed Central  Google Scholar 

  130. Amr KS, Ezzat WM, Elhosary YA, Hegazy AE, Fahim HH, Kamel RR. The potential role of miRNAs 21 and 199-a in early diagnosis of hepatocellular carcinoma. Gene. 2015;575(1):66–70.

    Article  PubMed  CAS  Google Scholar 

  131. Hu J, Wang Z, Tan CJ, Liao BY, Zhang X, Xu M, et al. Plasma microRNA, a potential biomarker for acute rejection after liver transplantation. Transplantation. 2013;95(8):991–9.

    Article  CAS  PubMed  Google Scholar 

  132. Sohn W, Kim J, Kang SH, Yang SR, Cho JY, Cho HC, et al. Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma. Exp Mol Med. 2015;47:e184.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  133. Sugimachi K, Matsumura T, Hirata H, Uchi R, Ueda M, Ueo H, et al. Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation. Br J Cancer. 2015;112(3):532–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009;361(15):1437–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Wang Y, Liang Z, Gao Y, Zhai D, Rao Q, Shi W, et al. Factors influencing circulating MicroRNA level in the studies of hepatocellular carcinoma biomarker. Neoplasma. 2015;62(5):798–804.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Liver Surgery Department, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, 20032, China

    Jian Zhou, Ao Huang & Xin-Rong Yang

Authors
  1. Jian Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ao Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xin-Rong Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jian Zhou.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhou, J., Huang, A. & Yang, XR. Liquid Biopsy and its Potential for Management of Hepatocellular Carcinoma. J Gastrointest Canc 47, 157–167 (2016). https://doi.org/10.1007/s12029-016-9801-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-016-9801-0

Keywords

Search

Navigation